This Binaytara Foundation's half-day virtual (online recorded materials and live web-based interactive discussions) conference will feature leading experts in multiple myeloma who will provide a comprehensive overview of current state and the future implications of B-cell Maturation Antigen (BCMA) directed therapies in multiple myeloma (MM). The goal of this activity is to improve the knowledge and the competence of participants to apply practice-changing clinical findings and expert recommendations to optimize clinical outcomes for patients with MM. The program features in-depth discussions and analysis focusing on multiple immunotherapeutic options with BCMA as the lead target. Expert faculty will highlight several current and emerging BCMA directed therapies including bispecific antibodies, CART, and ADC available for MM patients, and how to sequence them in an effective manner.
Format: Didactic lectures, case-based presentations, panel discussions.
2.5 AMA PRA Category 1 Credits™ - maximum
2.5 CNE contact hours
December 4, 2021